Neuralink, a company owned by Musk, has received a breakthrough device designation from the FDA for its "blindness" technology.

Market VisionWednesday, Sep 18, 2024 9:10 am ET

1min read

Elon Musk's brain-machine interface company Neuralink has announced that its experimental brain implant device, "Argus," has been granted "breakaway device" status by the U.S. Food and Drug Administration (FDA). The device is designed to help patients regain their vision.

Through its Breakaway Devices program, the FDA aims to expedite the development and review of more innovative medical devices, helping developers bring their products to market faster.

The FDA will provide priority review for products granted "breakaway device" status.

Shortly after Neuralink's announcement, Musk welcomed the FDA's decision.

Musk said: "Neuralink's Argus device will allow people who have lost their eyes and optic nerve to see again."

Neuralink has already implanted brain-computer interface (BCI) chips in two patients, with the aim of helping those with neurological diseases control external devices such as computers using only their thoughts. Musk previously revealed that Neuralink expects to implant another eight patients this year.

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.